2022 World Conference on Lung Cancer (ePosters)-EP14.05-010. Real-World Eligibility for Clinical Trials in Extensive Stage Small Cell Lung Cancer Patients

Pdf Summary

This study examined the eligibility criteria for the IMpower 133 and CASPIAN trials in real-world patients with extensive stage small cell lung cancer (ES-SCLC). The researchers found that a majority of these patients would not have met the eligibility criteria for these trials due to their strict criteria. The study also highlighted additional barriers to trial accrual in clinical practice, such as the fact that most ES-SCLC patients were treated within a week of initial consultation, leaving little time for trial enrollment. <br /><br />The IMpower 133 and CASPIAN trials had shown a survival benefit for ES-SCLC patients receiving chemotherapy plus immunotherapy. However, the strict eligibility criteria of these trials limit the generalizability of their findings and can impact trial accrual in real-world settings. <br /><br />The study analyzed data from stage IV SCLC patients at the Cancer Centre of Southeastern Ontario between 2016 and 2020. Patients were categorized as eligible or ineligible based on the criteria from the IMpower 133 and CASPIAN trials. The researchers summarized the clinical characteristics and trial eligibility using descriptive statistics and assessed overall survival using the Kaplan-Meier method. <br /><br />The results showed that the majority of patients would not have been eligible for the trials due to factors such as inadequate hematologic or end-organ function, the presence of symptomatic or untreated brain metastases, and an ECOG status of 2 or greater. The study also found that most patients were treated with chemotherapy within a week of diagnosis, further limiting their eligibility for clinical trials. <br /><br />Based on these findings, the authors suggest that future clinical trials should evaluate trial design and eligibility criteria to optimize the inclusion of ES-SCLC patients and better represent the real-world patient population. This could help improve the generalizability of trial findings and address the barriers to trial accrual in clinical practice.

Asset Subtitle

Navdeep Dehar

Meta Tag

Speaker Navdeep Dehar

Topic Small Cell Lung Cancer and Neuro-endocrine Tumours - RW/SOC

Keywords

eligibility criteria

IMpower 133

CASPIAN trials

real-world patients

extensive stage small cell lung cancer

ES-SCLC

trial accrual

chemotherapy plus immunotherapy

generalizability of findings

real-world settings